title: Efficacy of lactobionate-enriched cardioplegic solution in preserving compliance of cold-stored heart transplants.
abstract: Cardioplegic solutions of the extracellular type are commonly used as storage media for heart transplants. Because this type of formulation was not originally designed for preventing hypothermically induced edema, we assessed the effects of supplementing a standard, extracellular-like cardioplegic solution with the high molecular weight impermeant lactobionate on water content and postischemic compliance of isolated rat hearts. In one series of experiments, hearts were immersed in either a standard cardioplegic solution of the extracellular type or in the same solution supplemented with lactobionate (80 mmol/L). Hearts were then processed for measurements of water content after 4 hours, 6 hours, and 8 hours of storage at 4 degrees C. In a second series of experiments, hearts were stored in the same solutions for 4 hours and 8 hours and subsequently reperfused for 1 hour on a Langendorff column, at which time left ventricular pressure-volume curves were constructed and compared with those obtained during the preischemic perfusion. Lactobionate-treated hearts gained significantly less water than controls after 4 hours and 6 hours of storage, but the difference was no longer significant at the 8-hour time point. In contrast, the treated group yielded a significantly better recovery of compliance after both 4 hours and 8 hours of storage, suggesting that lactobionate might exert protective effects in addition to those caused by its impermeant properties, possibly involving calcium chelation and subsequent limitation of calcium-dependent contracture. Extracellular-type cardioplegic solutions are attractive because a single solution can be used during all phases of the transplantation procedure.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiovascular Surgery, Hôpital Lariboisière, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Menasché
authors.forename: B
authors.initials: B
authors.lastname: Hricak
authors.forename: F
authors.initials: F
authors.lastname: Pradier
authors.forename: S L
authors.initials: SL
authors.lastname: Cheav
authors.forename: C
authors.initials: C
authors.lastname: Grousset
authors.forename: C
authors.initials: C
authors.lastname: Mouas
authors.forename: G
authors.initials: G
authors.lastname: Albérici
authors.forename: G
authors.initials: G
authors.lastname: Bloch
authors.forename: A
authors.initials: A
authors.lastname: Piwnica
mesh_terms: D000818:Animals; D002314:Cardioplegic Solutions; D003187:Compliance; D003326:Coronary Circulation / Q000187:drug effects; D004187:Disaccharides / Q000494:pharmacology*; D006321:Heart / Q000502:physiology*; D016027:Heart Transplantation; D066298:In Vitro Techniques; D008297:Male; D009200:Myocardial Contraction; D015425:Myocardial Reperfusion; D009926:Organ Preservation; D051381:Rats; D017207:Rats, Sprague-Dawley; D016277:Ventricular Function, Left / Q000187:drug effects; D017725:Ventricular Pressure / Q000187:drug effects
chemical_list: D002314:Cardioplegic Solutions; D004187:Disaccharides; C005608:lactobionic acid